Base de dados : MEDLINE
Pesquisa : D02.886.675.867.060 [Categoria DeCS]
Referências encontradas : 5171 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 518 ir para página                         

  1 / 5171 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214780
[Au] Autor:Igase K; Igase M; Matsubara I; Sadamoto K
[Ad] Endereço:Department of Neurosurgery, Washokai Sadamoto Hospital, Ehime, Japan.
[Ti] Título:Mismatch between TOF MR Angiography and CT Angiography of the Middle Cerebral Artery may be a Critical Sign in Cerebrovascular Dynamics.
[So] Source:Yonsei Med J;59(1):80-84, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Although time-of-flight (TOF)-magnetic resonance angiography (MRA) can clearly depict intracranial arteries, the arterial flow of middle cerebral artery (MCA) is occasionally not detected. We evaluated this phenomenon with reference to cerebrovascular dynamics. MATERIALS AND METHODS: Seventeen patients with suspected occlusion of MCA or internal carotid artery on TOF-MRA were enrolled. All patients underwent CT angiography (CTA) and quantitative cerebral blood flow (CBF) examination for measurement of resting CBF and cerebrovascular reactivity (CVR). Depending on appearance, patients were categorized into three groups. Group A (n=6) had MCA delineation on both MRA and CTA, while groups B (n=6) and C (n=5) had no signal on MRA, but Group B had a MCA delineation on CTA. RESULTS: No significant difference between resting CBF and CBF after the administration of acetazolamide was seen among 3 groups. In contrast, mean CVR in group B was -19.7±18.1%, which was significantly lower than group A [36.4±21.7% (p<0.05)], but not than group C (21.4±35.2%). Furthermore, all patients in group B displayed a so-called steal phenomenon. CONCLUSION: This study is the first to show that visualization of MCA on TOF-MRA closely correlates with CVR, and that a vascular pattern showing no MCA signal intensity on MRA but with MCA delineation on CTA indicates a critical cerebrovascular condition.
[Mh] Termos MeSH primário: Circulação Cerebrovascular
Angiografia por Tomografia Computadorizada
Angiografia por Ressonância Magnética
Artéria Cerebral Média/diagnóstico por imagem
[Mh] Termos MeSH secundário: Acetazolamida/administração & dosagem
Idoso
Idoso de 80 Anos ou mais
Artéria Carótida Interna/fisiopatologia
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.80


  2 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226716
[Au] Autor:Hári-Kovács A; Soós J; Gyetvai T; Facskó A; Végh M
[Ad] Endereço:Szemészeti Klinika, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Korányi fasor 10-11., 6720.
[Ti] Título:[Case report on choroidal effusion after oral acetazolamide administration: an unusual manifestation of a well-known idiosyncratic effect?]
[Ti] Título:Acetazolamid orális alkalmazása mellett jelentkezo chorioidealeválás két esete: ismert idioszinkráziás hatás szokatlan megjelenési formája?.
[So] Source:Orv Hetil;158(50):1998-2002, 2017 Dec.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:Sulpha drugs are widely employed in medicine for various diseases and disorders. During the last several decades, numerous papers had been published on supra ciliary and posterior choroidal effusion likely presenting as an idiosyncratic effect of these drugs especially of acetazolamide. In each publication, the effusion was associated with either an acute angle-closure glaucoma or transitory myopia or both of these as leading symptoms. In the current publication, authors report on two cases where the acetazolamide-induced choroidal effusion was an accidental finding without either a myopic shift in refraction or an acute elevation in intraocular pressure. To our best knowledge, ours is the first report in the literature describing this unusual, "silent" form of a sulpha drug-induced choroidal effusion. Since the choroidal involvement may vary in size and location, and is not necessarily associated with acute glaucoma and myopia, one can assume that a considerable amount of acetazolamide-related ocular side-effects will not be discovered. The above case report aims to draw the attention of other specialities to the need for ophthalmic examination for their patients taking sulpha drugs with acute visual deterioration. Orv Hetil. 2017; 158(50): 1998-2002.
[Mh] Termos MeSH primário: Acetazolamida/efeitos adversos
Inibidores da Anidrase Carbônica/efeitos adversos
Doenças da Coroide/induzido quimicamente
[Mh] Termos MeSH secundário: Acetazolamida/administração & dosagem
Doença Aguda
Idoso de 80 Anos ou mais
Inibidores da Anidrase Carbônica/administração & dosagem
Doenças da Coroide/diagnóstico
Corpo Ciliar/patologia
Edema/induzido quimicamente
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carbonic Anhydrase Inhibitors); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1556/650.2017.30944


  3 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29023491
[Au] Autor:Huang Q; Chen R; Lin X; Xiang Z
[Ad] Endereço:Taizhou Hospital, Wenzhou Medical University, Taizhou, Zhejiang, PR China.
[Ti] Título:Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.
[So] Source:PLoS One;12(10):e0186180, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Carbonic anhydrase inhibitors (CAI) are often used in the treatment of cystoid macular edema (CME) in retinitis pigmentosa (RP) patients. The aim of this meta-analysis is to gain a better understanding of the overall efficacy of CAI treatment. METHODS: Databases including PubMed, EMBASE, and Cochrane Library were searched to identify relevant studies. Eligible studies were clinical trials of patients with RP assigned topical or oral CAIs such as dorzolamide and acetazolamide. Changes in central macular thickness (CMT) by OCT in µm and best-corrected visual acuity (BCVA) in log MAR equivalents were extracted and results compared between baseline and after treatment. RESULTS: 11 clinical reports were identified which included a total of 194 patients (358 eyes) available for analysis, with 59 patients (115 eyes) assigned oral CAI treatment and 135 patients (243 eyes) assigned topical CAI treatment. The combined results showed a significant reduction of macular edema, as calculated by baseline and final central macular thickness (CMT) based on OCT examination (46.02µm, 95%CI: -60.96, -31.08, I2 = 65%). However, the effect on visual acuity was inconsistent across studies. CONCLUSION: Based on non randomized controlled clinical studies, RP patients with CME who were treated with CAIs had better anatomical outcomes, but the effect on visual acuity was contradictory across studies. Multicenter prospective randomized controlled trials would be ideal to definitively test its clinical efficacy in RP patients.
[Mh] Termos MeSH primário: Inibidores da Anidrase Carbônica/administração & dosagem
Edema Macular/tratamento farmacológico
Retinite Pigmentosa/complicações
[Mh] Termos MeSH secundário: Acetazolamida/administração & dosagem
Acetazolamida/farmacologia
Administração Oral
Administração Tópica
Inibidores da Anidrase Carbônica/farmacologia
Ensaios Clínicos como Assunto
Feminino
Seres Humanos
Masculino
Estudos Prospectivos
Sulfonamidas/administração & dosagem
Sulfonamidas/farmacologia
Tiofenos/administração & dosagem
Tiofenos/farmacologia
Resultado do Tratamento
Acuidade Visual/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Carbonic Anhydrase Inhibitors); 0 (Sulfonamides); 0 (Thiophenes); 9JDX055TW1 (dorzolamide); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186180


  4 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28719377
[Au] Autor:Ferreira AO; Polonini H; da Silva SL; Aglio NCB; Abreu J; Fernandes BMA
[Ad] Endereço:Ortofarma - Quality Control Laboratories, Matias Barbosa, MG, Brazil.
[Ti] Título:Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4.
[So] Source:Int J Pharm Compd;21(4):339-346, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to evaluate the stability of 7 commonly used active pharmaceutical ingredients compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend SF PH4): acetazolamide 25.0 mg/mL, baclofen 10.0 mg/mL, dipyridamole 10.0 mg/mL, mebeverine hydrochloride 10.0 mg/mL, propylthiouracil 5.0 mg/mL, quinidine sulfate 10.0 mg/mL, and topiramate 5.0 mg/mL. All suspensions were stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by measuring the percentage recovery at varying time points throughout a 90-day period. Active pharmaceutical ingredient quantification was performed by ultraviolet (UV) high-performance liquid chromatography, via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredient + vehicle) was at least 90 days for all suspensions with regards to both temperatures. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.
[Mh] Termos MeSH primário: Composição de Medicamentos
Estabilidade de Medicamentos
[Mh] Termos MeSH secundário: Acetazolamida/química
Administração Oral
Baclofeno/química
Cromatografia Líquida de Alta Pressão
Dipiridamol/química
Frutose/análogos & derivados
Frutose/química
Fenetilaminas/química
Propiltiouracila/química
Quinidina/química
Suspensões
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phenethylamines); 0 (Suspensions); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 64ALC7F90C (Dipyridamole); 721M9407IY (Propylthiouracil); 7F80CC3NNV (mebeverine); H789N3FKE8 (Baclofen); ITX08688JL (Quinidine); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  5 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28701214
[Au] Autor:Hong EH; Ahn SJ; Lim HW; Lee BR
[Ad] Endereço:Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, #17 Haengdang-dong, Seongdong-gu, Seoul, 133-792, South Korea.
[Ti] Título:The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report.
[So] Source:BMC Ophthalmol;17(1):124, 2017 Jul 12.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss. We report a case of CME with HCQ retinopathy that improved with the use of oral acetazolamide, and discussed the possible mechanisms of CME in HCQ retinopathy using multimodal imaging modalities. CASE PRESENTATION: A 62-year-old patient with systemic lupus erythematosus (SLE) and HCQ retinopathy developed bilateral CME with visual decline. Fluorescein angiography (FA) showed fluorescein leakage in the macular and midperipheral area. After treatment with oral acetazolamide (250 mg/day) for one month, CME was completely resolved, best corrected visual acuity (BCVA) improved from 20/50 to 20/25, and FA examination showed decreased dye leakage in the macular and midperipheral areas. CONCLUSIONS: In cases of vision loss in HCQ retinopathy, it is important to consider not only progression of maculopathy, but also development of CME, which can be effectively treated with oral acetazolamide.
[Mh] Termos MeSH primário: Acetazolamida/administração & dosagem
Hidroxicloroquina/efeitos adversos
Edema Macular/tratamento farmacológico
Retina/patologia
Doenças Retinianas/induzido quimicamente
Acuidade Visual
[Mh] Termos MeSH secundário: Administração Oral
Antirreumáticos/efeitos adversos
Antirreumáticos/uso terapêutico
Inibidores da Anidrase Carbônica/administração & dosagem
Relação Dose-Resposta a Droga
Feminino
Angiofluoresceinografia
Fundo de Olho
Seres Humanos
Hidroxicloroquina/uso terapêutico
Lúpus Eritematoso Sistêmico/tratamento farmacológico
Edema Macular/diagnóstico
Edema Macular/etiologia
Meia-Idade
Retina/efeitos dos fármacos
Doenças Retinianas/complicações
Doenças Retinianas/diagnóstico
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antirheumatic Agents); 0 (Carbonic Anhydrase Inhibitors); 4QWG6N8QKH (Hydroxychloroquine); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-017-0517-0


  6 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28692063
[Au] Autor:Karimy JK; Zhang J; Kurland DB; Theriault BC; Duran D; Stokum JA; Furey CG; Zhou X; Mansuri MS; Montejo J; Vera A; DiLuna ML; Delpire E; Alper SL; Gunel M; Gerzanich V; Medzhitov R; Simard JM; Kahle KT
[Ad] Endereço:Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.
[Ti] Título:Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus.
[So] Source:Nat Med;23(8):997-1003, 2017 Aug.
[Is] ISSN:1546-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The choroid plexus epithelium (CPE) secretes higher volumes of fluid (cerebrospinal fluid, CSF) than any other epithelium and simultaneously functions as the blood-CSF barrier to gate immune cell entry into the central nervous system. Posthemorrhagic hydrocephalus (PHH), an expansion of the cerebral ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a common disease usually treated by suboptimal CSF shunting techniques. PHH is classically attributed to primary impairments in CSF reabsorption, but little experimental evidence supports this concept. In contrast, the potential contribution of CSF secretion to PHH has received little attention. In a rat model of PHH, we demonstrate that IVH causes a Toll-like receptor 4 (TLR4)- and NF-κB-dependent inflammatory response in the CPE that is associated with a ∼3-fold increase in bumetanide-sensitive CSF secretion. IVH-induced hypersecretion of CSF is mediated by TLR4-dependent activation of the Ste20-type stress kinase SPAK, which binds, phosphorylates, and stimulates the NKCC1 co-transporter at the CPE apical membrane. Genetic depletion of TLR4 or SPAK normalizes hyperactive CSF secretion rates and reduces PHH symptoms, as does treatment with drugs that antagonize TLR4-NF-κB signaling or the SPAK-NKCC1 co-transporter complex. These data uncover a previously unrecognized contribution of CSF hypersecretion to the pathogenesis of PHH, demonstrate a new role for TLRs in regulation of the internal brain milieu, and identify a kinase-regulated mechanism of CSF secretion that could be targeted by repurposed US Food and Drug Administration (FDA)-approved drugs to treat hydrocephalus.
[Mh] Termos MeSH primário: Hemorragia Cerebral/imunologia
Líquido Cefalorraquidiano/secreção
Plexo Corióideo/secreção
Hidrocefalia/imunologia
NF-kappa B/imunologia
Receptor 4 Toll-Like/imunologia
[Mh] Termos MeSH secundário: Acetazolamida/farmacologia
Animais
Antioxidantes/farmacologia
Western Blotting
Bumetanida/farmacologia
Hemorragia Cerebral/complicações
Ventrículos Cerebrais
Plexo Corióideo/efeitos dos fármacos
Plexo Corióideo/imunologia
Diuréticos/farmacologia
Técnicas de Silenciamento de Genes
Técnicas de Inativação de Genes
Hidrocefalia/etiologia
Hidrocefalia/metabolismo
Immunoblotting
Imuno-Histoquímica
Imunoprecipitação
Inflamação
Prolina/análogos & derivados
Prolina/farmacologia
Proteínas Serina-Treonina Quinases/metabolismo
Ratos
Ratos Wistar
Salicilanilidas/farmacologia
Membro 2 da Família 12 de Carreador de Soluto/metabolismo
Sulfonamidas/farmacologia
Tiocarbamatos/farmacologia
Receptor 4 Toll-Like/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Diuretics); 0 (NF-kappa B); 0 (Salicylanilides); 0 (Slc12a2 protein, mouse); 0 (Solute Carrier Family 12, Member 2); 0 (Sulfonamides); 0 (Thiocarbamates); 0 (Tlr4 protein, rat); 0 (Toll-Like Receptor 4); 0 (ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate); 0Y2S3XUQ5H (Bumetanide); 135467-92-4 (prolinedithiocarbamate); 9DLQ4CIU6V (Proline); EC 2.7.1.- (Stk39 protein, mouse); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); EUL532EI54 (closantel); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1038/nm.4361


  7 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28653390
[Au] Autor:Nieto Estrada VH; Molano Franco D; Medina RD; Gonzalez Garay AG; Martí-Carvajal AJ; Arevalo-Rodriguez I
[Ad] Endereço:Department of Critical Care Medicine, Hospital de San José, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
[Ti] Título:Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.
[So] Source:Cochrane Database Syst Rev;6:CD009761, 2017 06 27.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres (8202 feet). Acute hypoxia, acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude. In this review, the first in a series of three about preventive strategies for HAI, we assess the effectiveness of six of the most recommended classes of pharmacological interventions. OBJECTIVES: To assess the clinical effectiveness and adverse events of commonly-used pharmacological interventions for preventing acute HAI. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), Embase (OVID), LILACS and trial registries in January 2017. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus-based and free-text terms to search. SELECTION CRITERIA: We included randomized-controlled and cross-over trials conducted in any setting where commonly-used classes of drugs were used to prevent acute HAI. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by Cochrane. MAIN RESULTS: We included 64 studies (78 references) and 4547 participants in this review, and classified 12 additional studies as ongoing. A further 12 studies await classification, as we were unable to obtain the full texts. Most of the studies were conducted in high altitude mountain areas, while the rest used low pressure (hypobaric) chambers to simulate altitude exposure. Twenty-four trials provided the intervention between three and five days prior to the ascent, and 23 trials, between one and two days beforehand. Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level. Risks of bias were unclear for several domains, and a considerable number of studies did not report adverse events of the evaluated interventions. We found 26 comparisons, 15 of them comparing commonly-used drugs versus placebo. We report results for the three most important comparisons: Acetazolamide versus placebo (28 parallel studies; 2345 participants)The risk of AMS was reduced with acetazolamide (risk ratio (RR) 0.47, 95% confidence interval (CI) 0.39 to 0.56; I = 0%; 16 studies; 2301 participants; moderate quality of evidence). No events of HAPE were reported and only one event of HACE (RR 0.32, 95% CI 0.01 to 7.48; 6 parallel studies; 1126 participants; moderate quality of evidence). Few studies reported side effects for this comparison, and they showed an increase in the risk of paraesthesia with the intake of acetazolamide (RR 5.53, 95% CI 2.81 to 10.88, I = 60%; 5 studies, 789 participants; low quality of evidence). Budenoside versus placebo (2 parallel studies; 132 participants)Data on budenoside showed a reduction in the incidence of AMS compared with placebo (RR 0.37, 95% CI 0.23 to 0.61; I = 0%; 2 studies, 132 participants; low quality of evidence). Studies included did not report events of HAPE or HACE, and they did not find side effects (low quality of evidence). Dexamethasone versus placebo (7 parallel studies; 205 participants)For dexamethasone, the data did not show benefits at any dosage (RR 0.60, 95% CI 0.36 to 1.00; I2 = 39%; 4 trials, 176 participants; low quality of evidence). Included studies did not report events of HAPE or HACE, and we rated the evidence about adverse events as of very low quality. AUTHORS' CONCLUSIONS: Our assessment of the most commonly-used pharmacological interventions suggests that acetazolamide is an effective pharmacological agent to prevent acute HAI in dosages of 250 to 750 mg/day. This information is based on evidence of moderate quality. Acetazolamide is associated with an increased risk of paraesthesia, although there are few reports about other adverse events from the available evidence. The clinical benefits and harms of other pharmacological interventions such as ibuprofen, budenoside and dexamethasone are unclear. Large multicentre studies are needed for most of the pharmacological agents evaluated in this review, to evaluate their effectiveness and safety.
[Mh] Termos MeSH primário: Acetazolamida/uso terapêutico
Doença da Altitude/prevenção & controle
Edema Encefálico/prevenção & controle
Budesonida/uso terapêutico
Inibidores da Anidrase Carbônica/uso terapêutico
Dexametasona/uso terapêutico
Glucocorticoides/uso terapêutico
Hipertensão Pulmonar/prevenção & controle
[Mh] Termos MeSH secundário: Acetazolamida/efeitos adversos
Adolescente
Adulto
Idoso
Doença da Altitude/complicações
Doença da Altitude/epidemiologia
Edema Encefálico/epidemiologia
Edema Encefálico/etiologia
Inibidores da Anidrase Carbônica/efeitos adversos
Dexametasona/efeitos adversos
Seres Humanos
Hipertensão Pulmonar/epidemiologia
Meia-Idade
Parestesia/induzido quimicamente
Viés de Publicação
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Carbonic Anhydrase Inhibitors); 0 (Glucocorticoids); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009761.pub2


  8 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28615247
[Au] Autor:de Groot T; Doornebal J; Christensen BM; Cockx S; Sinke AP; Baumgarten R; Bedford JJ; Walker RJ; Wetzels JFM; Deen PMT
[Ad] Endereço:Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands.
[Ti] Título:Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.
[So] Source:Am J Physiol Renal Physiol;313(3):F669-F676, 2017 Sep 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lithium is the mainstay treatment for patients with bipolar disorder, but it generally causes nephrogenic diabetes insipidus (NDI), a disorder in which the renal urine concentrating ability has become vasopressin insensitive. Li-NDI is caused by lithium uptake by collecting duct principal cells and downregulation of aquaporin-2 (AQP2) water channels, which are essential for water uptake from tubular urine. Recently, we found that the prophylactic administration of acetazolamide to mice effectively attenuated Li-NDI. To evaluate whether acetazolamide might benefit lithium-treated patients, we administered acetazolamide to mice with established Li-NDI and six patients with a lithium-induced urinary concentrating defect. In mice, acetazolamide partially reversed lithium-induced polyuria and increased urine osmolality, which, however, did not coincide with increased AQP2 abundances. In patients, acetazolamide led to the withdrawal of two patients from the study due to side effects. In the four remaining patients acetazolamide did not lead to clinically relevant changes in maximal urine osmolality. Urine output was also not affected, although none of these patients demonstrated overt lithium-induced polyuria. In three out of four patients, acetazolamide treatment increased serum creatinine levels, indicating a decreased glomerular filtration rate (GFR). Strikingly, these three patients also showed a decrease in systemic blood pressure. All together, our data reveal that acetazolamide does not improve the urinary concentrating defect caused by lithium, but it lowers the GFR, likely explaining the reduced urine output in our mice and in a recently reported patient with lithium-induced polyuria. The reduced GFR in patients prone to chronic kidney disease development, however, warrants against application of acetazolamide in Li-NDI patients without long-term (pre)clinical studies.
[Mh] Termos MeSH primário: Acetazolamida/uso terapêutico
Diabetes Insípido Nefrogênico/tratamento farmacológico
Diuréticos/uso terapêutico
Capacidade de Concentração Renal/efeitos dos fármacos
Rim/efeitos dos fármacos
Cloreto de Lítio
Poliúria/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetazolamida/efeitos adversos
Idoso
Animais
Aquaporina 2/metabolismo
Pressão Sanguínea/efeitos dos fármacos
Diabetes Insípido Nefrogênico/induzido quimicamente
Diabetes Insípido Nefrogênico/fisiopatologia
Modelos Animais de Doenças
Diuréticos/efeitos adversos
Feminino
Taxa de Filtração Glomerular/efeitos dos fármacos
Seres Humanos
Rim/metabolismo
Rim/fisiopatologia
Masculino
Camundongos Endogâmicos C57BL
Meia-Idade
Países Baixos
Nova Zelândia
Concentração Osmolar
Projetos Piloto
Poliúria/induzido quimicamente
Poliúria/fisiopatologia
Estudos Prospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Aqp2 protein, mouse); 0 (Aquaporin 2); 0 (Diuretics); G4962QA067 (Lithium Chloride); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170616
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00147.2017


  9 / 5171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28557244
[Au] Autor:Abbas Q; Raza H; Hassan M; Phull AR; Kim SJ; Seo SY
[Ad] Endereço:Department of Biological Sciences, College of Natural Sciences, Kongju National University, 56 Gongjudehak-Ro 56, Gongju, Chungnam, 32588, Korea.
[Ti] Título:Acetazolamide Inhibits the Level of Tyrosinase and Melanin: An Enzyme Kinetic, In Vitro, In Vivo, and In Silico Studies.
[So] Source:Chem Biodivers;14(9), 2017 Sep.
[Is] ISSN:1612-1880
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Melanin is the major factor that determines skin color and protects from ultraviolet radiation. In present study we evaluated the anti-melanogenesis effect of acetazolamide (ACZ) using four different approaches: enzyme kinetic, in vitro, in vivo and in silico. ACZ demonstrated significant inhibitory activity (IC 7.895 ± 0.24 µm) against tyrosinase as compared to the standard drug kojic acid (IC 16.84 ± 0.64 µm) and kinetic analyses showed that ACZ is a non-competitive inhibitor without cytotoxic effect. In in vitro experiments, A375 human melanoma cells were treated with 20 or 40 µm of ACZ with or without 50 µm of l-DOPA. Western blot results showed that ACZ significantly (P < 0.05) decreased the expression level of tyrosinase at 40 µm. Zebrafish embryos were treated with 10, 20 or 40 µm of ACZ and of positive control kojic acid. At 72 h of treatment with ACZ and kojic acid, ACZ significantly (P < 0.001) decreased the embryos pigmentation to 40.8% of untreated embryos at the dose of 40 µm of ACZ while kojic acid decreased only 25.0% of pigmentation at the same dose of kojic acid. In silico docking were performed against tyrosinase using PyRx tool. Docking studies suggested that His244, Asn260 and His85 are the major interacting residues in the binding site of the protein. In conclusion, our results suggest that ACZ is a good candidate for the inhibition of melanin and it could be used as a lead for developing the drugs for hyperpigmentary disorders and skin whitening.
[Mh] Termos MeSH primário: Acetazolamida/farmacologia
Inibidores Enzimáticos/farmacologia
Melaninas/antagonistas & inibidores
Monofenol Mono-Oxigenase/antagonistas & inibidores
[Mh] Termos MeSH secundário: Agaricales/enzimologia
Animais
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Simulação por Computador
Seres Humanos
Melaninas/análise
Melaninas/metabolismo
Melanoma/enzimologia
Melanoma/metabolismo
Simulação de Acoplamento Molecular
Monofenol Mono-Oxigenase/análise
Monofenol Mono-Oxigenase/metabolismo
Pigmentação/efeitos dos fármacos
Pironas/farmacologia
Pigmentação da Pele/efeitos dos fármacos
Peixe-Zebra/embriologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Melanins); 0 (Pyrones); 6K23F1TT52 (kojic acid); EC 1.14.18.1 (Monophenol Monooxygenase); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170531
[St] Status:MEDLINE
[do] DOI:10.1002/cbdv.201700117


  10 / 5171 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28512741
[Au] Autor:Teachey W; Grayson J; Cho DY; Riley KO; Woodworth BA
[Ad] Endereço:Department of Otolaryngology , University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
[Ti] Título:Intervention for elevated intracranial pressure improves success rate after repair of spontaneous cerebrospinal fluid leaks.
[So] Source:Laryngoscope;127(9):2011-2016, 2017 Sep.
[Is] ISSN:1531-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES/HYPOTHESIS: Spontaneous cerebrospinal fluid (CSF) leaks are associated with increased intracranial pressure (ICP) and considered a manifestation of idiopathic intracranial hypertension. Although postoperative acetazolamide and placement of CSF shunt systems are considered valuable interventions for elevated ICP, the impact on recurrence rate remains unclear. The objective of this study was to systematically review evidence from reported literature to evaluate whether postoperative ICP management reduces recurrence rates after primary endoscopic repair. STUDY DESIGN: Prospective case series and systematic review. METHODS: Demographics, defect location, success rates, and ICP management in spontaneous CSF leak patients were prospectively collected over 8 years. A search was also conducted in PubMed to identify studies reporting cases of spontaneous CSF rhinorrhea. RESULTS: Fifty-six articles with nonduplicated data were identified and combined with a prospective series of 108 patients for a total of 679 patients treated for spontaneous CSF rhinorrhea. Average age was 50.4 years with 77% female. Average body mass index was 35.8 kg/m . Defects were most commonly located in the sphenoid sinus (n = 334) followed by the ethmoid (n = 318) and the frontal sinus (n = 46). Successful primary repair was 92.82% in patient cohorts where ICP evaluation and intervention with acetazolamide or CSF shunt systems was performed, but was significantly decreased to 81.87% in series with no active management of elevated ICP (P < .001). CONCLUSIONS: Evaluation and intervention for elevated ICP in spontaneous CSF leaks is associated with significantly improved success rates following primary endoscopic repair. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:2011-2016, 2017.
[Mh] Termos MeSH primário: Rinorreia de Líquido Cefalorraquidiano/terapia
Derivações do Líquido Cefalorraquidiano/métodos
Hipertensão Intracraniana/terapia
[Mh] Termos MeSH secundário: Acetazolamida/uso terapêutico
Anticonvulsivantes/uso terapêutico
Rinorreia de Líquido Cefalorraquidiano/complicações
Rinorreia de Líquido Cefalorraquidiano/patologia
Terapia Combinada
Seio Etmoidal/patologia
Seio Etmoidal/cirurgia
Feminino
Seres Humanos
Hipertensão Intracraniana/etiologia
Hipertensão Intracraniana/patologia
Masculino
Meia-Idade
Estudos Prospectivos
Recidiva
Seio Esfenoidal/patologia
Seio Esfenoidal/cirurgia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticonvulsants); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1002/lary.26612



página 1 de 518 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde